Neoadjuvant EGFR-TKI therapy in Non-Small cell lung cancer

被引：8
作者：
Grant, Christopher [1 ]
Nagasaka, Misako [1 ,2 ]
机构：
[1] Univ Calif Irvine, Med Ctr, Dept Med, Orange, CA USA
[2] Univ Calif Irvine, Med Ctr, Dept Med, Div Hematol & Oncol, Orange, CA USA
来源：
CANCER TREATMENT REVIEWS | 2024年 / 126卷
关键词：
Neoadjuvant targeted therapy; Perioperative targeted therapy; NEOADAURA; EGFR-mutant; Osimertinib; TYROSINE KINASE INHIBITOR; OPEN-LABEL; PHASE-III; OSIMERTINIB; GEFITINIB; RESISTANCE; ERLOTINIB; 1ST-LINE;
D O I：
10.1016/j.ctrv.2024.102724
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Non-small cell lung cancer (NSCLC) stages I-III are predominantly treated with surgery and combination immunotherapy and chemotherapy. A majority of these studies excluded patients with EGFR and ALK alterations. There are several completed and ongoing trials evaluating neoadjuvant treatment with EGFR-TKI monotherapy, combination therapy with chemotherapy, and combination therapy with immunotherapy. Here, we review completed clinical trials and discuss current ongoing trials' potential benefits, challenges, and future directions in the field.
引用
收藏
页数：8
相关论文
共 58 条
  • [1] [Anonymous], 2023, New analysis reveals potential effective drug combinations for treating lung cancer
  • [2] [Anonymous], Study Details | Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (Geometry Mono-1) | ClinicalTrials.gov
  • [3] [Anonymous], The Role of Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC: Who, When, and for How Long?
  • [4] [Anonymous], Study Details | Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations
  • [5] [Anonymous], STUDY DETAILS STUDY
  • [6] Aredo JV, 2023, J CLIN ONCOL, V41
  • [7] Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study
    Bian, Dongliang
    Sun, Liangdong
    Hu, Junjie
    Duan, Liang
    Xia, Haoran
    Zhu, Xinsheng
    Sun, Fenghuan
    Zhang, Lele
    Yu, Huansha
    Xiong, Yicheng
    Huang, Zhida
    Zhao, Deping
    Song, Nan
    Yang, Jie
    Bao, Xiao
    Wu, Wei
    Huang, Jie
    He, Wenxin
    Zhu, Yuming
    Jiang, Gening
    Zhang, Peng
    [J]. NATURE COMMUNICATIONS, 2023, 14 (01)
  • [8] Osimertinib as neoadjuvant therapy in a patient with stage IIIA non-small cell lung cancer: a case report
    Chen, Caroline Y.
    Fares, Charlene M.
    Shin, Daniel Sanghoon
    [J]. JOURNAL OF MEDICAL CASE REPORTS, 2021, 15 (01)
  • [9] Chen W Q, 2018, Zhonghua Zhong Liu Za Zhi, V40, P133, DOI 10.3760/cma.j.issn.0253-3766.2018.02.010
  • [10] Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach
    Engel, Julian
    Richters, Andre
    Getlik, Matthaeus
    Tomassi, Stefano
    Keul, Marina
    Termathe, Martin
    Lategahn, Jonas
    Becker, Christian
    Mayer-Wrangowski, Svenja
    Gruetter, Christian
    Uhlenbrock, Niklas
    Kruell, Jasmin
    Schaumann, Niklas
    Eppmann, Simone
    Kibies, Patrick
    Hoffgaard, Franziska
    Heil, Jochen
    Menninger, Sascha
    Ortiz-Cuaran, Sandra
    Heuckmann, Johannes M.
    Tinnefeld, Verena
    Zahedi, Rene P.
    Sos, Martin L.
    Schultz-Fademrecht, Carsten
    Thomas, Roman K.
    Kast, Stefan M.
    Rauh, Daniel
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (17) : 6844 - 6863
123456